IP Library Granted Patent US 10,258,651
Granted Patent B2
US 10,258,651 · App. 15/468,020 · Granted Apr 16, 2019

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

Inventors: Michel Revel (Rechovot, IL); Judith Chebath (Rechovot, IL); Michal Izrael (Rechovot, IL); Rosalia Kaufman (Rechovot, IL)
Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
A61K35/30C12N5/0619C12N5/0622C12N2501/11C12N2501/115C12N2501/155C12N2501/385C12N2501/41C12N2506/02C12N2533/52C12N2533/90G01N33/5058
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,651
App. No.
15/468,020
Granted
Apr 16, 2019
Kind
B2
Abstract

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Claims (14)

1. A method of treating one or more symptoms of amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the method comprising:

(a) culturing in suspension human embryonic stem cells in the presence of retinoic acid and Epidermal Growth Factor (EGF) to generate neurospheres;

(b) contacting the neurospheres with EGF on an adherent substrate, wherein the adherent substrate comprises an extracellular matrix component;

(c) dissociating the neurospheres following step (b) and contacting the dissociated neurospheres with a medium comprising EGF and Basic Fibroblast Growth Factor (bFGF);

(d) contacting the neurospheres following step (c) with a medium devoid of EGF and bFGF for 6-10 days, thereby generating astrocytes; and,

(e) directly transplanting the astrocytes into the central nervous system (CNS) of the subject.

2. The method of claim 1 , further comprising forming stem cell aggregates prior to step (a).

3. The method of claim 1 , wherein the concentration of EGF is 10-40 ng/ml.

4. The method of claim 1 , wherein the concentration of the retinoic acid is 1-50 μM.

5. The method of claim 1 , wherein step (a) is effected for 20-30 days.

6. The method of claim 1 , wherein the medium of step (c) comprises laminin and vitamin C.

7. The method of claim 1 , further comprising isolating the astrocytes following step (d).

8. The method of claim 1 , wherein the direct transplantation comprises an intrathecal injection of the astrocytes.

9. The method of claim 1 , wherein the subject is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: REVEL, MICHEL; CHEBATH, JUDITH; IZRAEL, MICHAL; KAUFMAN, ROSALIA
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 053450/0969 →
Continuity (4)
Division 14329510 · Jul 11, 2014
Continuation 12310495
Provisional Application 60840426 · Aug 28, 2006
Related Publication 20170362570A1 · Dec 21, 2017